TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06452316: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

Sponsor: Claris Biotherapeutics, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 75 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$745,008

Rescue Site Savings

+$496,672

Unlock Full NCT06452316 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06452316 Rescue Dossier →